In Embase, the following terms were used: ('sodium glucose cotransporter 2 inhibitor' OR 'SGLT2 inhibitor' OR empagliflozin OR dapagliflozin OR canagliflozin) AND ('heart failure with preserved ejection fraction' OR HFpEF OR 'diastolic heart failure') AND ('placebo' OR 'standard care' OR 'usual care'). The gene discussed is SLC5A2; the disease is diastolic heart failure.